| Literature DB >> 35885369 |
Yongshuai Jing1, Shilin Zhang1, Mingsong Li1, Yunfeng Ma1, Yuguang Zheng2, Danshen Zhang1, Lanfang Wu2.
Abstract
Coriolus is the dried fruiting body of Coriolus versicolor (L. ex Fr.) Quel. C. versicolor (CV) is a worldwide-distributed fungus, which is common and widely used in primitive forests in the northern hemisphere. Polysaccharide, as the main active ingredient in CV, has a variety of biological activities, such as promoting immune function, antivirus, antitumor, anti-diabetes, and so on. However, Coriolus versicolor polysaccharide (CVP) faces the problems of a single extraction method, lack of research on separation and purification, and the research on structural characterization is limited to the primary structure. Furthermore, the existing research results have not been systematically reviewed. Therefore, this paper summarizes the research status of CVP in terms of extraction technology, separation and purification, structural characterization, and pharmacological activity in recent years, in order to provide a theoretical basis for in-depth research, development, and utilization of CVP.Entities:
Keywords: Coriolus versicolor; bioactivities; extraction; polysaccharides; structure
Year: 2022 PMID: 35885369 PMCID: PMC9316838 DOI: 10.3390/foods11142126
Source DB: PubMed Journal: Foods ISSN: 2304-8158
Figure 1Overall research idea chart of CVP.
Extraction methods and yields of CVP.
| Experimental Method | Temperature | Time | Other Conditions | Yields | Ref. |
|---|---|---|---|---|---|
| Hot water extraction | 90 °C | 120 min | Material-to-liquid ratio of 1:30 (g:mL) | 5.38% | [ |
| 100 °C | 120 min | Ethanol concentration 95% | 6.98% | [ | |
| 85 °C | 105 min | Feed-to-liquid ratio of 1:27 | 7.27% | [ | |
| 100 °C | 180 min | Feed-to-liquid ratio of 1:50, 3 h | 4.39% | [ | |
| 80 °C | 180 min | Liquid nitrogen grinding | 16.1% | [ | |
| Enzyme extraction | 52 °C | 37 min | pH 5.5, | 9.58% | [ |
| 55 °C | 20 min | pH 6.0, | 3.26% | [ | |
| Ultrasonic extraction | Room temperature | 15 min | Material-to-liquid ratio of 1:20 (g:mL), ultrasonic extraction twice | 3.84% | [ |
| 45 °C | 50 min | pH 8.5, 2% Na2CO3 | 13.87% | [ | |
| Room temperature | 30 min | Material-to-liquid ratio of 1:45 (g:mL), ultrasonic power 450 W | 13.6% | [ |
Figure 2Two possible spatial speculative structures of CVP.
Figure 3Schematic diagram showing various biological activities of CVP.
CVP antioxidant activity index and research results.
| Vitro/Vivo | Effect | Ref. |
|---|---|---|
| In vitro | The scavenging activity of DPPH radical (64.9% at 0.8 mg/mL), O2•− radical | [ |
| IC50 (DPPH radical) = 0.388 mg/mL, IC50 (ABTS radical) = 0.419 mg/mL, IC50 (OH radical) = 4.423 mg/mL | [ | |
| The best scavenging activity of O2•− (60% at 5 mg/mL), OH radical (81% at 5 mg/mL) | [ | |
| IC50 = 0.832 g/mL | [ | |
| The best scavenging activity of ABTS radical (53% at 10 mg/mL), OH radical (72% at 5 mg/mL) | [ | |
| In vivo | SOD↑, GSH-Px↑, MDA↓ | [ |
| SOD↑, CAT↑ | [ | |
| Ox-LDL↓, SOD↑ | [ |
Notes: ↑, Increased; ↓, reduced.
Antitumor effects of CVP and its presumed mechanism.
| Cell/Animal | Effect | Speculative Mechanism | Ref. |
|---|---|---|---|
| Mouse melanoma B16 cells | ↓ | P53↓, Bcl-2↓ and Fas↓ | [ |
| Human cervical cancer HeLa cells | ↓ | Bcl-2↓ | [ |
| Human NK cells cultured in vitro | ↓ | NKG2Dreceptor↑ | [ |
| H22 liver cancer transplanted mice | ↓ | Its mechanism may might be related to immune regulation and promoting tumor cell apoptosis | [ |
| Human esophageal cancer cell line Eca-109 | ↓ | It acted on the inflammatory factor pathway CXCL12/CXCR4 | [ |
| Colorectal cancer cells | ↑ | CVP could improve the long-term efficacy in the treatment of patients with advanced colorectal cancer | [ |
| Mouse breast cancer 4T1 cells | ↓ | It has had antitumor and anti-metastatic effects on murine breast cancer 4T1 cells and 4T1 tumor mice | [ |
| Human promyelocytic leukemia HL-60 cells | ↓ | AP-1↑, EGR1↑ | [ |
| Leukemia HL-60 and U-937 cells | ↓ | PSP could disrupt the G1/S phase and G2/M phase during the cell cycle | [ |
| Human promyelocytic leukemia HL-60 cells | ↓ | 3H thymidine↓ | [ |
Notes: ↑, Increased; ↓, reduced; 4T1, breast cancer cells; AP-1, activator protein 1; Bcl-2, B-cell lymphoma 2; CXCL12, chemokines; CXCR4, chemokine receptor; EGR1, early growth response 1; Eca-109, human esophageal cancer cells; HL-60 cells, human promyelocytic leukemia cells; NK, natural killer cell; NKG2D, natural killer group 2 member D; P53, tumor suppressor gene; U-937 cells, human leukemia cell.
Immunomodulatory effect of CVP.
| Animal Model | Regulating Effect | Ref. |
|---|---|---|
| Sprague-Dawley rat model of cerebral ischemia-reperfusion injury | P-P38MAPK and caspase-3↓ | [ |
| Bone marrow cells from C57BL/6 mice | CD80 and CD86↑, IL-6, IL-12p40 and TFN-α↑ | [ |
| BALB/C mice infected with | TNF-α and IFN-γ↑, NO↓ | [ |
| Sarcoma-180 tumor bearing C57BLkunmingmice | IL-2, -4, -6, -10, -17A, and IFN-α, -γ↑ | [ |
| RAW264. 7 mouse monocyte/macrophage line | eNOS, iNOS, and TNF-α↑ | [ |
| ConA- or LPS-induced Kunming mice | Immune cells and cytokines↑ | [ |
| RAW264. 7 mouse monocyte/macrophage line | SR-B1↑, Dectin-1↑, CK2↑ | [ |
| Female BALB/c, C3H/HeJ, C3H/HeN mice | Membrane Ig and TLR4↑ | [ |
Notes: ↑, Increased in quantity or expression; ↓, reduced in quantity or expression; CD80, cluster of differentiation 80; CD86, cluster of differentiation 86; COA, concanavalin A; eNOS, endothelial nitric oxide synthase; IL-2, interleukin-2; IL-4, interleukin-4; IL-6, interleukin-6; IL-10, interleukin-10; IL-17, interleukin-17; IL-12p40, interleukin-12p40; INF-α, interferon α; INF-γ, interferon γ; iNOS, inducible nitric oxide synthase; LPS, lipopolysaccharide; NO, nitric oxide; p38 MAPK, p38 mitogen-activated protein kinase; SR-B1, high density lipoprotein receptor; TNF-α, tumor necrosis factor-α; TLR4, toll-like receptor 4.
Figure 4Analysis of 4441 patents browsed in ww.lens.org using the search terms “Coriolus Versicolor polysaccharide”: (A) patent applications per years; (B) document type; (C) jurisdictions (WO-WIPO, world intellectual property organization); (D) central product classification.